AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion.

The adjusted earnings were $2.12 per share, beating the consensus of $2.09.

AstraZeneca’s cancer business accounted for 45% of total sales. It increased 11% (+9% cc) to $7.03 billion.

Tagrisso sales were up 12% to $1.90 billion (+10% cc), Imfinzi revenues were up 39% (+37% cc) to $1.75 billion, Calquence sales increased 20% (+17% cc) to $967 million, and Lynparza sales increased 4% (+1% cc) to $878 million.

Cardiovascular, renal, and metabolism (CVRM) sales accounted for 20% of total sales, which fell 3% (-6% cc) ...